Literature DB >> 22504380

SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.

Puneet Singh1, Radhika Srinivasan, Jai Dev Wig.   

Abstract

OBJECTIVES: The present study screened the SMAD4 gene in an Indian population of patients with pancreatic ductal adenocarcinoma (PDAC) for the presence of homozygous deletions and mutations. The effect of these genetic alterations on Smad4 protein expression and patient survival was also evaluated.
METHODS: This study was conducted on surgically resected paired normal and tumor tissue samples of 25 consecutive patients with PDAC. The SMAD4 gene was screened for alterations by polymerase chain reaction and polymerase chain reaction-single-strand conformation polymorphism, followed by sequencing. The log-rank test was applied for survival analysis.
RESULTS: The SMAD4 gene was altered in 8 (32%) of the 25 cases, 3 cases (12%) by homozygous deletion, and 5 cases (20%) by mutations in the C-terminal MH2 domain. Eighty percent of the total mutations were located in the mutational hotspot, mutation cluster region, present within the C-terminal MH2 domain. Mutations did not always result in the complete absence of protein expression. SMAD4 genetic alterations significantly correlated with poor prognosis (5 vs 10 months, log-rank test; P = 0.001).
CONCLUSIONS: Most SMAD4 mutations are located in the mutational hotspot, mutation cluster region, present within MH2 domain. SMAD4 mutations affect Smad4 protein expression to different extents, depending on their location within the gene. SMAD4 gene alterations predict a worse outcome for patients with PDAC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504380     DOI: 10.1097/MPA.0b013e318247d6af

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  23 in total

Review 1.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.

Authors:  Stephanie E Combs
Journal:  Langenbecks Arch Surg       Date:  2015-07-03       Impact factor: 3.445

3.  Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.

Authors:  Joseph M Herman; Salma K Jabbour; Steven H Lin; Matthew P Deek; Charles C Hsu; Elliot K Fishman; Sinae Kim; John L Cameron; Marina Chekmareva; Daniel A Laheru; Amol K Narang; Timothy M Pawlik; Ralph H Hruban; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Pancreas       Date:  2018-02       Impact factor: 3.327

Review 4.  SMAD4 and its role in pancreatic cancer.

Authors:  Xiang Xia; Weidong Wu; Chen Huang; Gang Cen; Tao Jiang; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Tumour Biol       Date:  2014-12-03

Review 5.  [Will molecular diagnostics become established in pancreatic pathology?].

Authors:  B Sipos; J Sperveslage
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

6.  Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells.

Authors:  Xueying Zhang; Junxia Cao; Yujun Pei; Jiyan Zhang; Qingyang Wang
Journal:  Oncol Lett       Date:  2016-04-07       Impact factor: 2.967

Review 7.  An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression.

Authors:  Aamir Ali Khan; Xinhui Liu; Xinlong Yan; Muhammad Tahir; Sakhawat Ali; Hua Huang
Journal:  Cancer Metastasis Rev       Date:  2021-01-10       Impact factor: 9.264

Review 8.  Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.

Authors:  Hai-Feng Hu; Zeng Ye; Yi Qin; Xiao-Wu Xu; Xian-Jun Yu; Qi-Feng Zhuo; Shun-Rong Ji
Journal:  Acta Pharmacol Sin       Date:  2021-02-11       Impact factor: 7.169

9.  MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.

Authors:  Xiang Xia; Kundong Zhang; Gang Cen; Tao Jiang; Jun Cao; Kejian Huang; Chen Huang; Qian Zhao; Zhengjun Qiu
Journal:  Oncotarget       Date:  2015-08-28

10.  Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7.

Authors:  Shujie Cheng; Isaac Eliaz; Junfang Lin; Anita Thyagarajan-Sahu; Daniel Sliva
Journal:  Int J Oncol       Date:  2013-04-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.